tavr inflect earlier expect support low risk
thesi centera shutter surpris thesis-
alter expect pascal procedur momentum
improv back half rais pt
mse driven tavr growth mse procedur
volum world-wide begin benefit superior low risk data see
lesser extent util recoveri tavr guidanc rang
remain unchang manag point high end rang
comfort discuss mitral deliv vs
mse pascal procedur europ increas q/q destock
impact sale surgic growth vs mse increas
tavr volum partial off-set mix shift higher asp inspiri valv
guidanc remain unchang comfort midpoint
critic deliv growth vs mse driven hemospher
manag increas underli guidanc busi start
look durabl overal guidanc growth remain unchang
manag point top end rang comfort
earn deliv vs mse rais guidanc
midpoint line beat comfort
pleas see exhibit exhibit quarterli varianc full model
risk carri day outlook dilig post-acc see
suggest low-risk inflect would pronounc
intermedi risk clear indic creep began ahead fda
approv expect growth balanc academ
commun center increas confid greater inflect post-
approv expand reimburs ex us growth momentum also
acceler pt unexpect low-risk use
preval certain countri one quarter trend repres
revers multipl concern quarter europ backhalf
comfort ww tavr growth bp momentum deceler
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
impli tavr growth high end guidanc
conserv perhap ww util materi stronger across
board edward prudent earli expans low-risk
prudent addit assumpt account lotu roll-out
lost centera clinical/commerci sale stabil impli increment
sale backhalf increment bp total edward growth
bp tavr perform could see acceler referr
pattern continu shift fda approv subsequ reimburs
acceler volum growth updat tavr prior growth
impli momentum stabil comfort pend
addit low-risk data point better expect sale suggest
medtron estim prove conserv increment
sale bp cvg growth bp total
mitral improv lag expect pascal continu ramp mitral
miss preview case sale
headwind destock unexpect ii modest q/q
procedur growth vs expect given control roll-out model
sale respect driven
continu ramp pascal increas manufactur
capac cardioband dilig remain posit
channel enthusiasm pascal discuss post-tvt comfort
market growth support mitral sale current
mitraclip growth assumpt see
platform setback concern tvt see discuss centera
issu surround cathet deliveri system drove procedur
variabl fix issu possibl go take time cost money
cog associ valv go creat commerci
challeng rel evolut year ago centera defens hedg
self expand revolut light data highli reliabl
outcom balloon expand risk fallen manag direct
resourc platform includ potenti small version
centera valuabl edward also announc forma discontinu
expect alreadi extrem low product given feedback
mechan edward market leader structur heart
intervent continu invest heavili setback inevit
insignific includ cardiaaq evoqu cardioband harpoon one
afford invest much structur heart edward carri risk
opportun compani track record creat valu
exce risk
clinic updat mostli in-lin edward begin three us pivot trial
ye sapien progress pivot later year line
expect pascal clasp iif approv fda non-
inferior vs mitraclip begin come month pascal
tr tricupsid regurgit edward first tr pivot begin later
year cardioband tr pivot begin
thesi remain unchang post low-risk pt thesi rest two
dynam start materi low-risk driven inflect
tavr post-superior data see pascal prospect earlier
expect ce mark see increas pt prior
base base case ep support dcf
methodolog includ valu mitral
tavr market expans continu low risk mitral catalyst
tavr market expans continu low risk mitral catalyst
deriv discount cash flow model assum wacc
termin growth model project tavr market
growth billion drive ebit margin
incorpor valu reflect mitral option
edward maintain share market share tavr market grow
bn tavr increasingli becom therapi choic even low
risk patient drive penetr global mitral innov progress
faster expect price declin lower expect rate
price-to-earnings base analysi equival base ep support
price-to-earnings base analysi equival base ep support
tavr market reach bn global see gradual expans
low risk popul follow low risk data complement
growth rate higher risk us eu popul ew share declin
time remain market leader coapt result mitral path
forward key edward trial timelin launch need addit clariti
oper leverag acceler long-term margin reach
risk prove bridg far valv durabl remain oustand issu
younger patient still tavr market grow billion
limit low risk intermedi risk traction sapien share slip
traction acceler competit boston off-set
peer
long-term potenti market expans
lower risk patient remain
underappreci drive
out-performance time see market
expans billion said
near term intermedi risk penetr
durabl reflect growth inflect
continu see increment
ebitda margin tavr sale
drive long-term corpor ebit margin
high near term reinvest like
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reflect signific uncertainti
futur market
penetr tavr lower risk
popul critic near term
increas visibl structur heart
portfolio key durabl long term growth
risk data
risk achiev price
acceler competit
us near term robust
commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
mitral space market
opportun could larger aortic
least sever year away
reimburs structur us
europ could put downward pressur
price time
million except ep
sale
sale
sale
sale
equival
prepaid expens ca
net chang work capit
oper
invest intang asset
invest unconsolid affili
proce asset disposit
proce sale busi
proce note receiv
invest
proce issuanc long-term debt
payment long-term debt
proce issuanc short-term debt
payment short-term debt
chang equiti net tax benefit
payment relat ar securit net
financ
effect currenc exchang
